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Spending on outpatient prescription drugs accounts for a sub-
stantial share of total Medicaid expenditures—over $26 billion in 
2006. Controlling drug expenditures is a challenge for states: ris-
ing prices, high drug utilization, and increases in the Medicaid 
population all contribute to the growth of Medicaid outpatient 
prescription drug expenditures. State Medicaid programs do not 
purchase drugs directly; they reimburse pharmacies for covered 
drugs dispensed to Medicaid beneficiaries. Each state defines 
its pharmacy reimbursement formulas, which include the drug 
ingredient cost plus a dispensing fee. States are not allowed to 
use many cost containment tools (for example, closed drug for-
mularies, tiered copayments, mandatory mail order) used by pri-
vate purchasers to control drug spending, although they can use 
other tools such as prior authorization and generic substitution. 
Created by the Omnibus Reconciliation Act of 1990 (OBRA 1990), 
the Medicaid Drug Rebate Program helps lower Medicaid spend-
ing on outpatient prescription drugs by ensuring states receive 
discounts similar to those provided to private purchasers. While 
complicated, technical, and at times controversial, the Rebate 
Program has generated significant revenue for the states (and 
the federal government) that helps offset Medicaid prescription 
drug expenditures.
RebaTe agReeMenTs
In order for pharmaceutical manufacturers to obtain Medicaid 
coverage for their prescription drugs, they must sign a rebate 
agreement with the Secretary of Health and Human Servic-
es (HHS) to provide rebates for those drugs when purchased 
by Medicaid. Manufacturers pay the rebates directly to the 
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states, and the rebates are shared with the federal government. 
Approximately 550 drug manufacturers currently participate in 
the rebate program. Once a manufacturer enters into a rebate 
agreement, all of its prescription drugs are covered under Med-
icaid, subject to certain statutory exclusions.1 
besT PRice anD  
aveRage ManufacTuReR’s PRice 
Rebates are calculated for every outpatient prescription drug 
that states cover under Medicaid fee-for-service. Manufactur-
ers do not pay rebates for drugs provided in managed care set-
tings. The rebate amounts pharmaceutical manufacturers must 
pay are based on manufacturer-reported pricing data, namely 
the best price and average manufacturer’s price (AMP) for each 
drug, which are based on the prices and financial concessions 
(for example, volume discounts, other rebates, etc.) available to 
private purchasers. A drug’s best price and AMP are reported 
to the Centers for Medicare & Medicaid Services (CMS) by the 
manufacturer, but they are not publicly available.
Best price•   is the lowest manufacturer price paid for a drug by 
any purchaser (defined by the Medicaid statute as “any whole-
saler, retailer, provider, health maintenance organization 
(HMO), or nonprofit or government entity” with some excep-
tions2). A drug’s reported best price is required to reflect all 
discounts, rebates, and other pricing adjustments.
AMP•   is the average price wholesalers pay manufacturers for 
drugs that are sold to retail pharmacies. (The statute defines 
AMP as “the average price paid to a manufacturer for the drug 
in the United States by wholesalers for drugs distributed to the 
retail pharmacy class of trade.”) The transactions used to cal-
culate AMP are to reflect cash discounts and other reductions 
in the actual price paid.
RebaTes
Rebates are paid on both brand name and generic drugs. The 
brand name (known also as “innovator”) drug rebate is equal 
to 15.1 percent of AMP per unit (15.1% AMP), or the difference 
between AMP and best price per unit (AMP minus best price), 
whichever is greater. The relationship between best price and 
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AMP determines the size of the rebate; the closer best price is 
to AMP, the more likely the rebate will be based on 15.1% AMP 
(the minimum rebate amount). If a brand name drug’s AMP rises 
faster than inflation, an additional unit rebate amount is calculated 
based on the change in AMP compared with the consumer price 
index. The rebate amount for generic drugs is 11 percent of AMP 
per unit (11% AMP).
Rebate amounts are calculated and paid on a quarterly basis. 
Manufacturers must report the best price and AMP for each 
drug to CMS within 30 days of the end of each calendar quarter. 
CMS uses the pricing information to calculate the unit rebate 
amount for each drug and provides it to the states. Each state 
determines its Medicaid utilization for each covered drug in 
the quarter and reports this information to the manufacturer 
within 60 days of the end of the quarter. The manufacturer 
then computes and pays the rebate amount to each state within 
30 days of receiving the utilization information. States report 
rebate amounts received to CMS and share the rebates with the 
federal government based on their federal medical assistance 
percentage (FMAP). 
Rebate amounts have risen along with the increases in Medic-
aid drug spending. As a percentage of Medicaid drug spending, 
rebates increased from about 19 percent to 26 percent of Medicaid 
drug spending between 2001 and 2005. This increase is likely due 
to (i) a growing number of rebates calculated as the difference 
between AMP and best price, rather than the minimum; and (ii) 
a growing number of additional rebates due to drug prices climb-
ing faster than inflation. 
enDnoTes
1. Section 1927(d) of the Medicaid statute identifies 11 categories of drugs 
that states are allowed to exclude from coverage (for example, drugs 
for anorexia, weight gain/loss; drugs to promote fertility; drugs for 
cosmetic purposes or hair growth; barbiturates; benzodiazepines).
2. Exceptions to the best price include prices that are charged to certain 
federal purchasers (sales made through federal supply schedule, single-
award contract prices of any federal agency, federal depot prices, and 
prices charged to the Department of Defense, Department of Veterans 
Affairs, Indian Health Service, and the Public Health Service), eligible 
state pharmaceutical assistance programs and state-run nursing homes 
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enDnoTes ( continued)
 for veterans, and certain health care facilities, including those in un-
derserved areas or serving poorer populations. Prices negotiated by 
Medicare prescription drug plans or certain retiree prescription drugs 
plans are also excluded from best price. Nominal prices—prices that 
are less than 10 percent of AMP—also are excluded from best price.
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